Unknown

Dataset Information

0

Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.

ABSTRACT:

SUBMITTER: Cheung LC 

PROVIDER: S-EPMC6601077 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia.

Cheung Laurence C LC   Cruickshank Mark N MN   Hughes Anastasia M AM   Singh Sajla S   Chua Grace-Alyssa GA   Ford Jette J   Ferrari Emanuela E   Oommen Joyce J   Malinge Sébastien S   Lock Richard B RB   Kees Ursula R UR   Kotecha Rishi S RS  

Haematologica 20190124 7

Similar Datasets

Unknown Preclinical Evaluation of Carfilzomib for Infant <i>KMT2A</i>-Rearranged Acute Lymphoblastic Leukemia.
| S-EPMC8082024 | biostudies-literature
Unknown The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
| S-EPMC9168530 | biostudies-literature
Unknown Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.
| S-EPMC5220136 | biostudies-literature
Unknown Preclinical Assessment of Dactinomycin in &lt;i&gt;KMT2A&lt;/i&gt;-Rearranged Infant Acute Lymphoblastic Leukemia.
| S-EPMC11816686 | biostudies-literature
Unknown Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia.
| S-EPMC9018413 | biostudies-literature
Unknown Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.
| S-EPMC10687300 | biostudies-literature
Unknown Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
| S-EPMC9883157 | biostudies-literature
Unknown FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
| S-EPMC8763141 | biostudies-literature
Unknown Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.
| S-EPMC4468708 | biostudies-literature
Unknown The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia.
| S-EPMC12508131 | biostudies-literature